Elsevier

Biomaterials

Volume 33, Issue 28, October 2012, Pages 6823-6832
Biomaterials

Controlled release of dexamethasone from peptide nanofiber gels to modulate inflammatory response

https://doi.org/10.1016/j.biomaterials.2012.06.003Get rights and content

Abstract

New biomaterials that have the ability to locally suppress an immune response could have broad therapeutic use in the treatment of diseases characterized by acute or chronic inflammation or as a strategy to facilitate improved efficacy in cell or tissue transplantation. We report here on the preparation of a modular peptide amphiphile (PA) capable of releasing an anti-inflammatory drug, dexamethasone (Dex), by conjugation via a labile hydrazone linkage. This molecule self-assembled in water into long supramolecular nanofibers when mixed with a similar PA lacking the drug conjugate, and the addition of calcium salt to screen electrostatic repulsion between nanofibers promoted gel formation. These nanofiber gels demonstrated sustained release of soluble Dex for over one month in physiologic media. The Dex released from these gels maintained its anti-inflammatory activity when evaluated in vitro using a human inflammatory reporter cell line and furthermore preserved cardiomyocyte viability upon induced oxidative stress. The ability of this gel to mitigate the inflammatory response in cell transplantation strategies was evaluated using cell-surrogate polystyrene microparticles suspended in the nanofiber gel that were then subcutaneously injected into mice. Live animal luminescence imaging using the chemiluminescent reporter molecule luminol showed a significant reduction in inflammation at the site where particles were injected with Dex-PA compared to the site of injection for particles within a control PA in the same animal. Histological evidence suggested a marked reduction in the number of infiltrating inflammatory cells when particles were delivered within Dex-PA nanofiber gels, and very little inflammation was observed at either 3 days or 21 days post-implantation. The use of Dex-PA could facilitate localized anti-inflammatory activity as a component of biomaterials designed for various applications in regenerative medicine and could specifically be a useful module for PA-based therapies. More broadly, these studies define a versatile strategy for facile synthesis of self-assembling peptide-based materials with the ability to control drug release.

Introduction

One major challenge in the field of biomaterials is to develop strategies to combat the innate host inflammatory response [1], [2]. Many commonly used biomaterials, including collagen and alginate, elicit some cell-mediated immune response at the implantation site [3], [4], [5], [6], [7]. Though a mild innate immune response is part of the normal healing process following implantation of a foreign material, such a response could prove detrimental when combined with the delivery and transplantation of fragile cells, islets, or tissue [8], [9], [10], [11]. Using biomaterials to deliver therapeutic cells adds additional factors that could influence the inflammatory response, including issues of cell source or transplant location. For example, strategies delivering autologous cells as therapy for cardiovascular disease have demonstrated limited efficacy, resulting in part from the enhanced inflammatory environment of ischemic tissue [12]. Islet transplantation to combat type 1 diabetes mellitus, meanwhile, relies on allogeneic (or even xenogeneic) tissue sources, which makes managing the inflammatory response paramount for effective therapy [11]. Strategies to combat immune-destruction of transplanted islets have included immunoisolation through encapsulation in biomaterials, but such strategies have demonstrated only limited success thus far as the construct size is often too big for injection and the encapsulation results in limitations to nutrient and oxygen transport [13], [14], [15]. The development of new materials that actively mitigate the local host immune response and facilitate improved efficacy in cell or tissue transplantation therefore remains an important objective.

One approach that has been used to modulate the host immune response is to design biomaterials with controlled release of anti-inflammatory drugs such as dexamethasone (Dex), a potent steroidal anti-inflammatory and immune response-suppressing drug [16]. In addition, Dex is known to be an important signaling molecule to promote differentiation in bone marrow-derived stromal cells and mesenchymal stem cells [17], [18], [19], [20], [21]. In order to harness its anti-inflammatory function or to stimulate stem cell differentiation, non-covalent Dex incorporation and release has been included in the design of a number of biomaterials [22], [23], [24], [25], [26], [27]. Several constructs incorporating this drug have been evaluated in vivo, demonstrating a significant reduction in the post-implant inflammatory response to a material [28] and also promoting osteogenesis in transplanted stem cells when its release is combined into the delivery scaffold [29], [30]. In a few instances, biomaterials have been designed to control the release of Dex using covalent attachment via hydrolyzable linkages, including hydrazones and lactide esters, which are labile in aqueous conditions to release the free drug [31], [32], [33], [34], [35].

Over the last decade, our group and others have investigated self-assembling peptide-based materials for applications in regenerative medicine, drug delivery, and cancer [36], [37], [38], [39], [40], [41], [42], [43], [44], [45], [46]. In particular, our group has focused on a class of molecules, termed peptide amphiphiles (PAs), which contain a short peptide sequence covalently attached to a saturated alkyl tail and self-assemble into fiber-like nanostructures [47], [48]. The assembly of these molecules occurs through hydrophobic collapse of their alkyl tails and hydrogen bonding leading to the formation of β-sheet structures near the core of the nanofiber [49], [50]. On the end opposite the hydrophobic tail, PAs can be synthesized to contain a bioactive peptide designed to interact with biological targets such as cell receptors [51], [52], biopolymers [53], [54], or proteins [55]. In other systems, PAs can be integrated with commonly used biomaterials such as collagen or poly(l-lactic acid) [56], [57]. The conserved amphiphilic molecular design enables the modular construction of PA nanofibers that combine different PA molecules within the same assembled nanofiber as a way to multiplex different bioactivities or optimize the spacing of bioactive ligands [55], [58].

We report here the design, synthesis, and function of a PA that could allow controlled release of Dex through the use of a hydrazone linkage. While previous attempts to combine drug release with PA technology have focused on solubilizing hydrophobic drugs in the lipid core of the assembled fiber [59], [60], [61], this approach using covalent attachment via a hydrazone could facilitate enhanced control over the kinetics of drug release [62], [63]. A Dex-releasing PA (Dex-PA) could potentially be easily integrated with other bioactive PAs to therapeutically reduce or eliminate the immune response. In this work, a PA conjugated with Dex was synthesized and PA nanofiber gels were prepared that could release the soluble drug over a period of several weeks. Using in vitro methods, we evaluated the anti-inflammatory and cytoprotective activity of released Dex. Finally, an in vivo model was used to evaluate the ability of the Dex-PA to mitigate the inflammatory response to cell surrogate microparticles delivered within a Dex-PA nanofiber gel.

Section snippets

Dex-PA synthesis

Rink Amide MBHA resin and Fmoc-protected amino acids were purchased from EMD. Dex was purchased from Spectrum and used as received. All solvents were ACS reagent grade and purchased from Mallinckrodt. Other peptide synthesis reagents were purchased from commercial sources and used as received. 1-[N, N, N′-Tris((tert-butyloxycarbonyl))hydrazide]-adipic acid (HAA(Boc)3) was synthesized as previously described and used to synthesize a PA containing a free hydrazide, as also described previously,

PA design and characterization

The Dex-PA was designed to release free Dex over time in physiological conditions through the use of a hydrolyzable hydrazone linkage. Briefly, tri-Boc-hydrazido adipic acid (HAA(Boc)3) was synthesized as previously described [62] and added to a PA with the sequence C16–V2A2E2K via the ε-amine of the lysine residue on resin after selective removal of an Mtt protecting group on the lysine. Following cleavage in 95% TFA, a stabile hydrazide was generated. After purification by HPLC, the

Conclusions

We have described a peptide amphiphile conjugated covalently through a labile hydrazone bond to the steroidal anti-inflammatory drug dexamethasone. This material, along with similar drug-conjugated peptide amphiphiles, could be useful as gel networks to provide prolonged and localized drug delivery at the site of injection. In this work, we showed through in vitro studies the cytoprotective and anti-inflammatory properties of this material. Additionally, in vivo studies in mice demonstrated the

Acknowledgments

This work was supported by NIH grant number 5R01DE015920. JBM was supported by an NIH postdoctoral fellowship (1F32AR061955-01) and MJW was supported by the NIH through the Northwestern University Regenerative Medicine Training Program (5T90-DA022881). Additionally, support was provided through a Northwestern Feinberg School of Medicine Dixon Translational Research Stewardship Award. The authors also gratefully acknowledge helpful discussions with Prof. Dong Wang (University of Nebraska), Prof.

References (79)

  • T. Hickey et al.

    Dexamethasone/PLGA microspheres for continuous delivery of an anti-inflammatory drug for implantable medical devices

    Biomaterials

    (2002)
  • Q. Wang et al.

    Injectable PLGA based colloidal gels for zero-order dexamethasone release in cranial defects

    Biomaterials

    (2010)
  • T. Ito et al.

    Anti-inflammatory function of an in situ cross-linkable conjugate hydrogel of hyaluronic acid and dexamethasone

    Biomaterials

    (2007)
  • T.T. Dang et al.

    Spatiotemporal effects of a controlled-release anti-inflammatory drug on the cellular dynamics of host response

    Biomaterials

    (2011)
  • H. Kim et al.

    In vivo bone formation by human marrow stromal cells in biodegradable scaffolds that release dexamethasone and ascorbate-2-phosphate

    Biochem Biophys Res Commun

    (2005)
  • X. Shi et al.

    Microsphere-based drug releasing scaffolds for inducing osteogenesis of human mesenchymal stem cells in vitro

    Eur J Pharm Sci

    (2010)
  • J.B. Matson et al.

    Peptide self-assembly for crafting functional biological materials

    Curr Opin Solid State Mater Sci

    (2011)
  • T.D. Sargeant et al.

    Hybrid bone implants: self-assembly of peptide amphiphile nanofibers within porous titanium

    Biomaterials

    (2008)
  • M.J. Webber et al.

    Development of bioactive peptide amphiphiles for therapeutic cell delivery

    Acta Biomater

    (2010)
  • S. Sur et al.

    A hybrid nanofiber matrix to control the survival and maturation of brain neurons

    Biomaterials

    (2012)
  • A. Mata et al.

    Bone regeneration mediated by biomimetic mineralization of a nanofiber matrix

    Biomaterials

    (2010)
  • M.R. Kapadia et al.

    Nitric oxide and nanotechnology: a novel approach to inhibit neointimal hyperplasia

    J Vasc Surg

    (2008)
  • W.F. Liu et al.

    Real-time in vivo detection of biomaterial-induced reactive oxygen species

    Biomaterials

    (2011)
  • B. Beutler

    Tlr4: central component of the sole mammalian LPS sensor

    Curr Opin Immunol

    (2000)
  • J.M. Anderson et al.

    Monocyte, macrophage and foreign body giant cell interactions with molecularly engineered surfaces

    J Mater Sci Mater Med

    (1999)
  • S. Ghanaati et al.

    Evaluation of the tissue reaction to a new bilayered collagen matrix in vivo and its translation to the clinic

    Biomed Mater

    (2011)
  • S. Ghanaati et al.

    Tissue reaction to sealing materials: different view at biocompatibility

    Eur J Med Res

    (2010)
  • M.J. Cooke et al.

    Neural differentiation regulated by biomimetic surfaces presenting motifs of extracellular matrix proteins

    J Biomed Mater Res A

    (2010)
  • R.F. Gibly et al.

    Advancing islet transplantation: from engraftment to the immune response

    Diabetologia

    (2011)
  • S. Frantz et al.

    Post-infarct remodelling: contribution of wound healing and inflammation

    Cardiovasc Res

    (2009)
  • E.S. O'Sullivan et al.

    Islets transplanted in immunoisolation devices: a review of the Progress and the challenges that Remain

    Endocr Rev

    (2011)
  • H. Zimmermann et al.

    Alginate-based encapsulation of cells: past, present, and future

    Curr Diab Rep

    (2007)
  • Z. Hamidouche et al.

    Autocrine fibroblast growth factor 18 mediates dexamethasone-induced osteogenic differentiation of murine mesenchymal stem cells

    J Cell Physiol

    (2010)
  • Z. Hamidouche et al.

    FHL2 mediates dexamethasone-induced mesenchymal cell differentiation into osteoblasts by activating Wnt/beta-catenin signaling-dependent Runx2 expression

    FASEB J

    (2008)
  • M.F. Pittenger et al.

    Multilineage potential of adult human mesenchymal stem cells

    Science

    (1999)
  • M.F. Pittenger et al.

    Human mesenchymal stem cells: progenitor cells for cartilage, bone, fat and stroma

    Curr Top Microbiol Immunol

    (2000)
  • M.F. Pittenger

    Mesenchymal stem cells from adult bone marrow

    Methods Mol Biol

    (2008)
  • T. Hickey et al.

    In vivo evaluation of a dexamethasone/PLGA microsphere system designed to suppress the inflammatory tissue response to implantable medical devices

    J Biomed Mater Res

    (2002)
  • M.S. Kim et al.

    In vivo osteogenic differentiation of rat bone marrow stromal cells in thermosensitive MPEG-PCL diblock copolymer gels

    Tissue Eng

    (2006)
  • Cited by (205)

    View all citing articles on Scopus
    1

    MJW and JBM contributed equally to this work.

    View full text